AbbVie’s fast-acting Botox rival just hit a regulatory wall, but not where investors feared
AbbVie’s TrenibotulinumtoxinE faces an FDA manufacturing CRL. Find out what this means for approval, aesthetics and neurotoxins.
Pharma & Biotech
Pharma & Biotech
How Galderma is repositioning Restylane Contour beyond cheeks into full-face structural correction
FDA approval of Restylane Contour for temple hollowing signals a shift in facial aesthetics. Discover what this means for the industry and future treatments.
Medical Devices & Diagnostics
Is this the end of EMFACE lookalikes? Inside BTL’s cross-border IP enforcement playbook
BTL’s EMFACE wins global IP battle against WonderFace. Find out how this reshapes the energy-based facial therapy market in 2026.